Our Patent licensees :
Luciano et al:
- PREMED Inc http://www.predmed.com/products
- Stanford University (cross immunity agreement).
U.S. Patent Number 6,503,705
U.S. Patent Number 5,856,086
U.S. Patent Number 5,650,268
U.S. Patent Number 5,631,128
News, Press releases (Patents)
HepatiC® trademark registration
ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252.
The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antiviral Agents which has been developed together with the Spanish Association for Liver Diseases.
Exclusive licensing agreement with CRP-Santé for “COMET” software
ABL entered into an exclusive worldwide licensing agreement with CRP-Santé for its COMET software designed for high performance DNA sequencing analysis and classification.See full Press Release.
ABL acquires Evivar Medical Assets and further enhances its IT Solutions and Personalized Healthcare Platform for Hepatitis B, Hepatitis C and HIV Infections
Please see the full Press Release at Businesswire
South African Patent
ABL is pleased to report the South African Patent Office has been issued patent N° 2009/07533 and has been granted for 20 years from the filing date, April 10, 2008. This patent is related to the Emory Patent Internal Application WO/2008/124192.
ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL’s TherapyEdge®-ViroScore® Platform
LUXEMBOURG–(BUSINESS WIRE)–Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA’s HIV resistance interpretation system.
ABL will offer virco®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge® HIV. virco®TYPE HIV-1 results (raw data and report) will be available together with full patient’s details and will support the healthcare providers’ virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.
ABL Licensed CRP-Santé COMET Subtyping Tool
Advanced Biological Laboratories (ABL) S.A. and Luxembourg Centre de Recherche Public pour la Santé CRP-Santé announced a non-exclusive licensing and distribution agreement to implement CRP-Santé COMET subtyping tool on ABL TherapyEdge® Platform.
Centro de Genomas®
ABL is pleased to announce that Centro de Genomas® is as of Oct 15th 2009 the TherapyEdge® local agent in Brazil and will present the TherapyEdge® and ViroScore® products at the “XVI Congresso Brasileiro de Infectologia” which will be held from October the 18th to October the 21st at Maceió, BRAZIL.
See the brochure
If you are interested in our patents, please contact us at ABLPatents@ablsa.com